drugset / Trial / NCT07692256

the Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients

NCT07692256

Phase 2 Recruiting 60 enrolled Ain Shams University
RandomizedParallel-groupTriple-blindTreatment

Summary

the study to investigate the efficacy of empagiflozin in pediatric heart failure

Timeline

Start
2025-12-01
Primary completion
2026-12-01
Completion
2027-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 0.25 mg/kg Other
Subject Empagliflozin Small molecule 0.5 mg/kg Other

Indications